¾¨Ó㴫ý

Saturday 21 December 2024
Salisbury Foundation Trust

FOI_8289

Internal Reference Number: FOI_8289

Date Request Received: 14/11/2024 00:00:00

Date Request Replied To: 10/12/2024 00:00:00

This response was sent via: By Email

Request Summary: Treatment for Myelofibrosis

Request Category: Researcher



 
Question Number 1:
Please provide the total number of patients treated in the last 6 months for:

• Polycythaemia Vera (ICD10 code D45)

• Myelofibrosis (ICD10 code D47.4)

• Myelofibrosis (ICD10 code D47.4) patients aged 65 and older
 
Answer To Question 1:
Please see our response to this question in the spreadsheet attached.

To accompany this answer to question 1 please also see the documents listed below:

 12597 - FOI_8289 - Treatment for Myelofibrosis Q1.xlsx
 
Question Number 2:
How many patients were treated in the past 6 months (for any disease) with:

• Ruxolitinib

• Fedratinib

• Momelotinib
 
Answer To Question 2:
How many patients were treated in the past 6 months (for any disease) with:

• Ruxolitinib - 12 patients

• Fedratinib - 0

• Momelotinib - 5 patients
 
Question Number 3:
How many patients were treated with Ruxolitinib in the past 6 months for the following diseases?

• Myelofibrosis (ICD10 code D47.4)

• Polycythaemia Vera (ICD10 code D45)

• Other/Unknown
 
Answer To Question 3:
How many patients were treated with Ruxolitinib in the past 6 months for the following diseases?

• Myelofibrosis (ICD10 code D47.4) - 10 patients

• Polycythaemia Vera (ICD10 code D45) - <5 patients

• Other/Unknown
 
Question Number 4:
How many myelofibrosis (ICD10 code D47.4) patients has your trust diagnosed in the past 3 years?

• Of these patients, how many were treated in the past 6 months with Hydroxycarbamide?

• Of these patients, how many were treated in the past 6 months with Interferon therapy?

• Of these patients, how many have received no active treatment in the past 6 months?

 
Answer To Question 4:
How many myelofibrosis (ICD10 code D47.4) patients has your trust diagnosed in the past 3 years? - < 5 patients

• Of these patients, how many were treated in the past 6 months with Hydroxycarbamide? - <5 patients

• Of these patients, how many were treated in the past 6 months with Interferon therapy? - 0 patients

• Of these patients, how many have received no active treatment in the past 6 months? - <5 patients
 
Question Number 5:
Does your trust participate in any clinical trials for the treatment of myelofibrosis? If so, can you please provide the name of each trial along with the number of patients taking part.
 
Answer To Question 5:
No.
Please see Attachments:
 
To return to the list of all the FOI requests please click here

Our staff at Salisbury District Hospital have long been well regarded for the quality of care and treatment they provide for our patients and for their innovation, commitment and professionalism. This has been recognised in a wide range of achievements and it is reflected in our award of ¾¨Ó㴫ý Foundation Trust status. This is afforded to hospitals that provide the highest standards of care.

Person Centred & Safe

Professional

Responsive

Friendly

Progressive

¾¨Ó㴫ý, Salisbury District Hospital, Odstock Road, Salisbury, Wiltshire, SP2 8BJ
T: 01722 336262 E: sft.pals@nhs.net
© 2024 ¾¨Ó㴫ý
Trust Values